US FDA approves Jazz Pharmaceuticals’ Modeyso to treat recurrent H3 K27M-mutant diffuse midline glioma: Dublin Friday, August 8, 2025, 11:00 Hrs [IST] Jazz Pharmaceuticals plc, ...

Kelley Mack of 'The Walking Dead' passed away at 33 following her battle with glioma. Learn about her diagnosis symptoms and ...

Kelley Mack, who portrayed Addy in Season 9 of The Walking Dead, has died at the age of 33. Her family announced that Mack ...

The FDA has granted accelerated approval to Modeyso (dordaviprone) for the treatment of diffuse midline glioma harboring an ...

Kelley Mack, an actor who starred in "The Walking Dead," died due to complications from the COVID-19 vaccine. Actor Kelley ...

Kelley Mack’s death on Aug. 2 at age 33 was "very unexpected," her rep tells PEOPLE. The 'Walking Dead' actress was still ...

Modeyso is the first and only approved treatment for recurrent H3 K27M-mutant diffuse midline glioma in patients aged one ...

The actress, voice artist, and producer, Kelly Mack, died on August 2, 2025, in her hometown of Cincinnati, Ohio. The news of ...

The US FDA has given accelerated approval to Jazz Pharma for Modeyso to treat adult and paediatric patients with diffuse midline glioma.

The FDA granted accelerated approval to dordaviprone for the treatment of patients aged 1 year and older with recurrent diffuse midline glioma who harbor the H3 K27M mutation with progressive disease ...

Modeyso is the first drug to treat patients with diffuse midline glioma with an H3 K27M mutation, an ultra-rare and aggressive brain tumor.